SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy DD. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97107.
  • 2
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 173345.
  • 3
    Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 (Suppl. 1): S479.
  • 4
    Kane M. Epidemiology of hepatitis B infection in North America. Vaccine 1995; 13 (Suppl. 1): S167.
  • 5
    Fattovich G, Brollo L, Alberti A, et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990; 10: 1416.
  • 6
    Tong MJ, Sampliner RE, Govindarajan S, Co RL. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology 1987; 7: 7138.
  • 7
    Davis GL, Hoofnagle JH. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985; 102: 7625.
  • 8
    Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 2305.
  • 9
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 93662.
  • 10
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.
  • 11
    McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32 (4 Pt 1): 8426.
  • 12
    Marcellin P, Giostra E, Martinot-Peignoux M, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100 (5 Pt 1): 14324.
  • 13
    Levy P, Marcellin P, Martinot-Peignoux M, et al. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990; 12 (3 Pt 1): 5704.
  • 14
    Vento S, Di Perri G, Luzzati R, et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989; 1: 3323.
  • 15
    Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67: 4550.
  • 16
    Ishiga K, Kawatani T, Suou T, et al. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 2001; 73: 1158.
  • 17
    Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 1828.
  • 18
    Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 232430.
  • 19
    Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 10859.
  • 20
    Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 4479.
  • 21
    Vento S, Di Perri G, Garofano T, Concia E, Bassetti D. Reactivation of hepatitis B in AIDS. Lancet 1989; 2: 1089.
  • 22
    Carman WF, Korula J, Wallace L, et al. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 14067.
  • 23
    Kubo S, Nishiguchi S, Hamba H, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001; 233: 13945.
  • 24
    Rostoker G, Rosenbaum J, Ben Maadi A, et al. Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome. Nephron 1990; 56: 224.
  • 25
    Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 9117.
  • 26
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 292530.
  • 27
    Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 7245.
  • 28
    Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl. 1): 1079.
  • 29
    Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996; 78: 22105.
  • 30
    Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299307.
  • 31
    Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 2004; 12: 1916.
  • 32
    Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 5406.
  • 33
    Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000; 60: 24955.
  • 34
    McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 3643.
  • 35
    Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116: 1669.
  • 36
    Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 3948.
  • 37
    Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999; 81: 6974.
  • 38
    Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005; 55: 82831.
  • 39
    Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 28996.
  • 40
    Chen PM, Chiou TJ, Fan FS, et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 1999; 67: 142533.
  • 41
    Silvestri F, Ermacora A, Sperotto A, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000; 108: 3946.
  • 42
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 5862.
  • 43
    Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 2705.
  • 44
    Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 193944.
  • 45
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202.
  • 46
    Lau GK, Liang R, Wu PC, et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998; 28: 35968.
  • 47
    Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003; 44: 75966.
  • 48
    Ter Borg F, Smorenburg S, De Man RA, et al. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 226770.
  • 49
    Lau JY, Bird GL, Gimson AE, Alexander GJ, Williams R. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 1991; 337: 802.
  • 50
    Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398402.
  • 51
    Gish RG, Lau JY, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 17.
  • 52
    Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 165761.
  • 53
    Dornsife RE, Averett DR. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother 1996; 40: 5149.
  • 54
    Swartz MN. Mitochondrial toxicity – new adverse drug effects. N Engl J Med 1995; 333: 11468.
  • 55
    Tanikawa K, Hayashi N, Ichida F. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection. Hepatology 1997; 26: 259A (abstract).
  • 56
    Ter Borg F, Smorenburg S, De Man RA. Successful treatment with lamivudine for fulminant hepatic failure caused by chemotherapy-induced hepatitis B virus reactivation. Gastroenterology 1997; 112: A1399 (abstract).
  • 57
    Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 3967.
  • 58
    Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000; 33: 46975.
  • 59
    Perrillo RP, Rakela J, Martin P. Lamivudine for hepatitis B after liver transplantation. Hepatology 1996; 24: 182A (abstract).
  • 60
    Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 3857.
  • 61
    Picardi M, Selleri C, De Rosa G, et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 12679.
  • 62
    Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 2639.
  • 63
    Lee WC, Wu MJ, Cheng CH, et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 107481.
  • 64
    Cainelli F, Longhi MS, Concia E, Vento S. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001; 96: 16512.
    Direct Link:
  • 65
    Al-Taie OH, Mork H, Gassel AM, et al. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 1999; 78: 2479.
  • 66
    Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 24951.
    Direct Link:
  • 67
    Henkes M, Martin S, Einsele H, Aulitzky WE. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation. Ann Hematol 2002; 81: 3436.
  • 68
    Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 11828.
  • 69
    Chan HL, Chui AK, Lau WY, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004; 18: 295300.
  • 70
    Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 145662.
  • 71
    Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy – a prospective case series. Am J Hematol 2005; 80: 197203.
  • 72
    Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11: 1417.
  • 73
    Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005; 28: 37984.
  • 74
    Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 20915.
  • 75
    Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597603.
  • 76
    El-Sayed MH, Shanab G, Karim AM, et al. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report. Pediatr Hematol Oncol 2004; 21: 14556.
  • 77
    Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 17429.
  • 78
    Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001; 65: 4737.
  • 79
    Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 3916.
  • 80
    Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001; 68: 2924.
  • 81
    Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 1997; 4 (Suppl. 1): 1116.
  • 82
    Endo T, Sakai T, Fujimoto K, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2001; 27: 4336.
  • 83
    Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004; 99: 236975.
    Direct Link:
  • 84
    Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, Santoscoy M, Nieto-Cisneros L. Lamivudine-induced pure red cell aplasia. Am J Hematol 2000; 65: 18991.
  • 85
    Hester EK, Peacock JE Jr. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 1998; 12: 43940.
  • 86
    Tseng A, Conly J, Fletcher D, et al. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Clin Infect Dis 1998; 27: 9089.
  • 87
    Endo T, Sawada K, Fujimoto K, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki 2000; 41: 3228.
  • 88
    Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21: 24353.
  • 89
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 618.
  • 90
    Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 127682.
  • 91
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 92
    Caccamo L, Romeo R, Rossi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 18692.
  • 93
    Pelizzari AM, Motta M, Cariani E, et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004; 5: 3258.
  • 94
    Chen PM, Yao NS, Wu CM, et al. Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation 2002; 74: 1828.
  • 95
    Dai MS, Lu JJ, Chen YC, Perng CL, Chao TY. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001; 92: 292732.
  • 96
    Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80: 64353.
  • 97
    Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 93743.
  • 98
    Lampertico PP, Viganò MM, Manenti EE, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 14149.
  • 99
    Benhamou YY, Thibault VV, Vig PP, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 627.
  • 100
    Cortelezzi A, Vigano M, Zilioli VR, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006; 35: 4679.
  • 101
    Simpson ND, Simpson PW, Ahmed AM, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 2003; 37: 6871.
  • 102
    Su WP, Wen CC, Hsiung CA, et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 2005; 11: 52838.
  • 103
    Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 130611.
  • 104
    Zekri AR, Mohamed WS, Samra MA, et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004; 13: 30511.
  • 105
    Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 559.
  • 106
    Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8: 5314.
  • 107
    Yuen MF, Tanaka Y, Lai CL. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 2003; 46: 3736.
  • 108
    Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 13208.
  • 109
    Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991; 21: 3605.